NCT02070549 2025-02-13
Trametinib in Treating Patients With Advanced Cancer With or Without Hepatic Dysfunction
National Cancer Institute (NCI)
Phase 1 Completed
Clinical Trials
9 trialsNCT01231594 2019-03-22
A Rollover Study to Provide Continued Treatment With GSK2118436 to Subjects With BRAF Mutation-Positive Tumors
Novartis
Phase 1 Completed
NCT01192165 2017-11-13
Safety and Tolerability Study of GSK1120212, a MEK Inhibitor, in Combination With Docetaxel, Erlotinib, Pemetrexed, Pemetrexed + Carboplatin, Pemetrexed + Cisplatin, or Nab-Paclitaxel
GlaxoSmithKline
Phase 1 Completed
NCT01371487 2017-11-13
GSK1120212 Food-effect Study
GlaxoSmithKline
Phase 1 Completed
NCT01387204 2017-11-13
Study to Investigate the Absorption, Distribution, Metabolism and Elimination of [14C]GSK1120212
GlaxoSmithKline
Phase 1 Completed
NCT01416337 2017-11-13
Absolute Bioavialability of GSK1120212
GlaxoSmithKline
Phase 1 Completed
NCT01647659 2017-11-13
Relative Bioavailibilty for Pediatric Powder for Suspension (PfOS) Formulation
GlaxoSmithKline
Phase 1 Completed
NCT01658553 2017-11-13
A Study to Look at the Electrical Activity of the Heart in Subjects With Solid Tumor Cancers, Before and After Receiving the Study Treatment, GSK1120212
GlaxoSmithKline
Phase 1 Completed
NCT01231581 2013-09-26
Study of GSK1120212 Plus Gemcitabine vs Placebo Plus Gemcitabine in Metastatic Pancreatic Cancer
GlaxoSmithKline
Phase 2 Completed